In patients with recurrent ovarian cancer, the antibody-drug conjugate mirvetuximab soravtansine co-administered with bevacizumab, has shown anti-tumor activity that leads to lasting responses in platinum “agnostic” cases (resistant/sensitive), with strong folate receptor alpha expression (FR-α) [38]. Here, FOLR1 is linked to ovarian cancer.